Roche has announced the launch of its comprehensive Liver Disease Panel, a suite of certified algorithms designed to help clinicians better identify and manage chronic liver disease (CLD).
By bringing together biomarker-based diagnostics and advanced digital algorithms, including the CE-marked algorithm LiverPRO, the Liver Disease Panel supports better-informed clinical decisions, from timely fibrosis risk identification to the surveillance of liver cancer.
Chronic liver disease represents a growing global health challenge, with 1.5 billion people affected worldwide. CLD remains widely undiagnosed, as early stages may often present without symptoms, leading to missed opportunities for early intervention and avoidable progression to advanced disease, which can include cirrhosis and liver cancer. The drivers behind CLD are wide-ranging. In addition, the increasing prevalence of metabolic conditions like MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) now affects 38% of the global population and is becoming the fastest-growing cause of liver cancer worldwide.
The Liver Disease Panel is designed to support clinical decision-making across key stages of the chronic liver disease pathway, from timely risk identification and disease assessment to treatment guidance in future versions of the panel. By combining complementary biomarkers within advanced digital algorithms, the panel helps clinicians make more confident, evidence-based decisions using routinely available clinical data.
In leveraging advanced biomarkers, like Elecsys PRO-C3 within powerful digital tools like ADAPT and now LiverPRO, the Liver Disease Panel transforms the patient journey by enabling broader reach and timely patient detection through a scalable approach to assessing fibrosis severity. Through the integration of biomarker innovation with algorithm analysis, the Liver Disease Panel reduces reliance on invasive tests and provides a proactive, preventive model of care.
Roche is investing in digital innovation to advance the standard of care in liver disease. Through a collaboration with the health tech company Evido, the Liver Disease Panel includes LiverPRO, an innovative algorithm that adapts to existing patient data - requiring only age and a minimum of three out of nine common blood-based biomarkers to assess the risk of liver fibrosis. By leveraging accessible routine laboratory results, LiverPRO supports timely intervention, helping clinicians act sooner and improving disease management before patients reach advanced stages of the disease. LiverPRO has been endorsed in the EASL Patient Trajectory Guidance as an alternative and scalable first-line test for liver fibrosis, confirming that the tool standardises patient referrals and speeds up the identification of high-risk cases using a non-invasive technology.
The Liver Disease Panel represents Roche’s first comprehensive digital portfolio of biomarker and digital algorithm solutions designed to support care across key stages of the chronic liver disease pathway. This includes conditions along the liver disease spectrum, including metabolic dysfunction-associated steatotic liver disease (MASLD) to metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC).
This library brings together clinically validated algorithms into a single, secure platform. It combines tools like LiverPRO for likelihood of having liver fibrosis, ADAPT with Roche's Elecsys PRO-C3 for assessing severity of liver fibrosis, and GAAD with Roche's Elecsy AFP and Elecsys PIVKA II for aid in diagnosis of hepatocellular carcinoma (HCC) - with trusted clinical tools such as the FIB-4 Index, MELD Scores, ALBI Score, Child-Pugh Score, and the Lille Model. Each solution is certified and automated within clinical workflows, ensuring patient data is handled with the highest standards required for a medical device.
The Liver Disease Panel, available on the navify Algorithm Suite, marks a significant step in Roche’s strategy to provide digital health solutions for the growing global burden of chronic liver disease. It seamlessly integrates with existing hospital systems, giving clinicians a single point of access to order and view algorithm results. The Liver Disease Panel will be available in markets across Europe.